Abstract
BackgroundWe have previously reported the efficacy and safety results of ustkeinumab (UST), an IL-12/23 p40 inhibitor, in patients with active psoriatic arthritis up to two years of UST treatment from...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have